Abstracts tagged "interferons"

Abstract Number: 802 • 2015 ACR/ARHP Annual Meeting
Identification of Cyclin-Dependent Kinase 1 As a Novel Regulator for Controlling Type I Interferon Signaling in Systemic Lupus Erythematosus
Lingling Wu¹, Bo Qu¹, Yuting Qin¹ and Nan Shen^1,2, ¹Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²The Center for Autoimmune Genomics and Etiology (CAGE),Cincinnati Children’s Hospital Medical Center,Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose: Type I interferon (IFN) signaling has been a central pathogenic pathway in systemic lupus erythematosus (SLE). The application of specific inhibitors of IFN pathway has emerged…
Abstract Number: 3220 • 2015 ACR/ARHP Annual Meeting
Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial
Xiang Guo¹, L Wang², G Illei³, P Brohawn¹, Brandon Higgs¹ and Wendy White¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²MedImmune, Gaithersburg, MD, ³Clinical Development, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). A Phase IIb randomized,…
Abstract Number: 2927 • 2014 ACR/ARHP Annual Meeting
Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis
Priyanka Vashisht¹, Jessica M. Dorschner², Mark A. Jensen³, Beverly Chrabot⁴, Theresa Wampler Muskardin⁵, Marlena Kern⁶, Tetrad Investigators⁷, ABCoN Consortium⁸, S. Louis Bridges Jr.^9,10, P.K. Gregersen¹¹ and Timothy B. Niewold², ¹Division of Rheumatology and Department of Immunology, University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁶North Shore Univ Hospital, Feinstein Institute for Medical Research, Manhasset, NY, ⁷AL, ⁸NY, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹¹The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose Response to tumor necrosis factor alpha (TNF-α) inhibition is variable in rheumatoid arthritis (RA). Previous studies have suggested that circulating type I interferon (IFN)…
Abstract Number: 2843 • 2014 ACR/ARHP Annual Meeting
SLE Patients Carrying a Disease-Associated PTPN22 R620W Variant Show Reduced Interferon-Inducing Capacity
Yaya Wang¹, David Ewart², Ami Yamamoto², Emily C. Baechler¹, Parastoo Fazeli³ and Erik J. Peterson², ¹Medicine, University of Minnesota, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN, ³Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN
Background/Purpose Type 1 interferons (IFN) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). Increased expression of IFN-regulated genes, termed the IFN-signature, correlates with…
Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Yasin Keskin¹, Emire Seyahi², Cagri Poyraz³, Serdal Ugurlu¹, Yilmaz Ozyazgan⁴ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Psychiatry, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Istanbul, Turkey, ⁴Department of Ophthalmology, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…
Abstract Number: 2500 • 2014 ACR/ARHP Annual Meeting
Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients
Jacob Sode^1,2,3, Ulla Vogel⁴, Steffen Bank^5,6, Paal Skytt Andersen⁷, Merete Lund Hetland^8,9, Henning Locht³, Niels H. H. Heegaard^10,11 and Vibeke Andersen^1,5,12,13, ¹Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ²Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, ³Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ⁴National Research Centre for the Working Environment, Copenhagen, Denmark, ⁵Medical Department, Viborg Regional Hospital, Viborg, Denmark, ⁶Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, ⁷Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ¹⁰Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ¹¹Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark, ¹²Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, ¹³Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark
Genetic Variation in the TLR5 Locus is Associated with Anti-TNF Response among Rheumatoid Arthritis PatientsBackground/Purpose: In a recent study (paper in press) of Danish rheumatoid…
Abstract Number: 2093 • 2014 ACR/ARHP Annual Meeting
Improvement of Rituximab Response Prediction in Rheumatoid Arthritis Via Correction for Prednisone-Related Suppression of Type I Interferon Response Gene Expression
Tamarah D. de Jong¹, Saskia Vosslamber¹, Marjolein Blits¹, Gertjan Wolbink², Michael T. Nurmohamed^2,3, Connie J. van der Laken⁴, Gerrit Jansen⁵, Alexandre E. Voskuyl⁵ and Cornelis L. Verweij⁶, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁶Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Elevated type I IFN response gene (IRG) expression has been described to be clinically relevant in predicting the non-response to rituximab in rheumatoid arthritis…
Abstract Number: 1793 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of IFN-Alpha in Induction and Maintenance of Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). Single Center Observational Study
Benjamin Seeliger¹, Martin Foerster¹, Anne Moeser¹, Janett Happe¹, Claus Kroegel¹ and Thomas Neumann², ¹Jena University Hospital, Internal Medicine I, Jena, Germany, ²Jena University Hospital, Internal Medicine III, Jena, Germany
Background/Purpose: To evaluate the efficiency and safety of IFN-alpha in induction and maintenance of remission in patients with EGPA and to describe its effects on…
Abstract Number: 1625 • 2014 ACR/ARHP Annual Meeting
Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles
Kimberly Carroll¹, Elizabeth Mitton-Fitzgerald¹, Brittany Bettendorf², Claudia Gohr¹, Mary E. Cronin¹ and Ann K. Rosenthal³, ¹Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²Internal Medicine/Pediatrics, Medical College of Wisconsin, Wauwatosa, WI, ³Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Microparticles (MPs) are circulating membrane-bound vesicles derived from blood and endothelial cells via a highly regulated process. They are immunomodulatory and have been implicated…
Abstract Number: 1619 • 2014 ACR/ARHP Annual Meeting
Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs
David Drubin¹, Xiang Guo², Linglin Yang³, Rong Zeng³, Yuling Wu³, Mustimbo EliPollard Roberts³, Reynald Lescarbeau¹, Aaron Van Hooser¹, Michael Macoritto¹, Michelle Petri⁴ and Wendy White⁵, ¹Selventa, Cambridge, MA, ²Translational Sciences, MedImmune LLC, Gaithersburg, MD, ³MedImmune LLC, Gaithersburg, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose Interferons (IFNs) have long been implicated in the pathogenesis of systemic lupus erythematosus (SLE). However, the specific consequences of the IFN activity have not…
Abstract Number: 1617 • 2014 ACR/ARHP Annual Meeting
Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes
Zhongbo Jin¹, Mark A. Jensen², Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin³, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁶, Kevin G. Moder⁴, Vaidehi Chowdhary³ and Timothy B. Niewold¹, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁶Dept of Rheumatology, Mayo Clinc, Rochester, MN
Background/Purpose Type I interferon (IFN) is a primary pathogenic factor in human systemic lupus erythematosus (SLE). IFN gene expression signatures have been observed in whole blood and mixed peripheral…
Abstract Number: 872 • 2014 ACR/ARHP Annual Meeting
Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia
Danieli Andrade¹, Mimi Kim², Luz P. Blanco³, S. Ananth Karumanchi⁴, Gloria Koo⁵, Patricia M. Redecha⁶, Kyriakos A. Kirou¹, Angela M. Alvarez⁷, Melissa J. Mulla⁷, Mary K. Crow⁸, Vikki Abrahams⁷, Mariana J. Kaplan³ and Jane E. Salmon⁹, ¹Hospital for Special Surgery, New York, NY, ²Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁶Rheumatology Research, Hospital for Special Surgery, New York, NY, ⁷Yale School of Medicine, New Haven, CT, ⁸Department of Medicine, Hospital for Special Surgery, New York, NY, ⁹Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Pregnant patients with SLE are at increased risk of placental insufficiency and preeclampsia, disorders associated with angiogenic factor imbalance. IFN-α, a critical element in…
Abstract Number: 861 • 2014 ACR/ARHP Annual Meeting
Ultraviolet B Generates Type 1 Interferon and Induces Autoantibody-Mediated Disease in a Mouse Model of Cutaneous Lupus
Clayton Sontheimer¹ and Keith B. Elkon², ¹Pediatric Rheumatology, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions often contain plasmacytoid dendritic cells (pDC). The mechanisms…
Abstract Number: 764 • 2014 ACR/ARHP Annual Meeting
ERG and FLI1 in Systemic Sclerosis-Associated Pulmonary Complications
Rong Han and Maria Trojanowska, Arthritis Center, Boston University, Boston, MA
Background/Purpose: Pulmonary arterial hypertension (PAH) and pulmonary fibrosis (PF) are the two major lung complications associated with the autoimmune disease systemic sclerosis (SSc), and constitute…
Abstract Number: 641 • 2014 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase Inhibition Mitigates NET Formation and Protects Against Kidney, Skin, and Vascular Disease in Lupus-Prone MRL/Lpr Mice
Jason S. Knight¹, Venkataraman Subramanian², Alexander A. O'Dell¹, Srilakshmi Yalavarthi¹, Wenpu Zhao³, Carolyne K. Smith³, Jeffrey B. Hodgin⁴, Paul Thompson² and Mariana J. Kaplan³, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²The Scripps Research Institute, Jupiter, FL, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Department of Pathology, University of Michigan, Ann Arbor, MI
Background/Purpose: An imbalance between neutrophil extracellular trap (NET) production and NET degradation has been observed in systemic lupus erythematosus (SLE), potentially contributing to autoantigen externalization,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].